Slide 1: Clinical Stage Antiviral Drug Development Company
BIOTRON LIMITED (ASX:BIT) Clinical Stage An;viral Drug Development Company Michelle Miller CEO & Managing Director +61 (0) 412 313 329 mmiller@biotron.com.au
Slide 2: Forward Looking Statements
Forward Looking Statements This presenta,on may contain forward-‐looking statements with respect to the financial condi,on, results and business achievements/performance of Biotron Limited and certain of the plans and objec,ves of its management. These statements are statements that are not historic
Slide 3: Biotron Limited Overview
Biotron Limited Overview • Clinical stage an,viral drug development company • Focus on developing novel small molecule drugs • Clinical programs for Hepa,,s C virus (HCV) and HIV • Earlier stage programs include Dengue and others • Headquartered in Sydney, Australia • Key recent highlights • Mar 201
Slide 4: Biotron - Advanced Pipeline of Clinical Programs
Biotron -‐ Advanced Pipeline of Clinical Programs VIRAL INDICATION DISCOVERY PRE-‐CLINICAL PHASE 1a PHASE 1b PHASE 2a PHASE 2b STATUS TARGET Ph 2a complete; HEP C p7 Ph 2b (3 mth dosing) scheduled for 4Q13 Ph 1b/2a HIV Vpu complete Ph 2 Hep C/HIV Vpu/p7 In progress Dengue M Next Ready for IND-‐ g
Slide 5: BIT225 and Hepatitis C
BIT225 and Hepa;;s C • New inves,ga,onal oral drug for trea,ng HCV infec,on • First in class; targets p7 protein – essen,al for virus assembly and release • Preclinical studies – synergism with IFN/RBV and polymerase inhibitors • Three completed trials: § Phase Ia –Single dose, dose-‐escala,ng saf
Slide 6: BIT225 HCV Phase 2 Clinical Information
BIT225 HCV Phase 2 Clinical Informa;on Median log reduc;on % Complete EVR % ETVR Treatment at 35 days (<50IU/ml at 12 weeks) (<50IU/ml at 48 weeks) 400 mg BIT225 + IFN/RBV -‐4.957 86 100 200 mg BIT225 + IFN/RBV -‐4.351 88 88 Placebo + IFN/RBV -‐3.649 63 75 • Clear demonstra,on that this first in c
Slide 7: BIT225 and HIV
BIT225 and HIV • BIT225 also has potent an,-‐HIV ac,vity – Unique mode of ac,on targets HIV “hiding” in long-‐lived reservoir cells • Reservoirs are last of the holy grail in HIV * • No exis,ng drugs target this source of HIV in the body • Phase 2a trial of BIT225 in HIV-‐infected subjects recent
Slide 8: BIT225 - HIV / HCV Co-Infected Population
BIT225 -‐ HIV / HCV Co-‐Infected Popula;on • 25 – 40% of HIV-‐infected people in the USA are also HCV-‐infected – Significantly worse prognosis than mono-‐infected pa,ents – US and European regulatory agencies have stated the need for new treatment strategies for this difficult-‐to-‐treat popula
Slide 9: Biotron Programs Summary
Biotron Programs Summary • Documented need for new an,viral drugs • Licensing space is very ac,ve • BIT225 has shown good clinical efficacy against both HCV and HIV • Poten;al to be used with new (DAA) or exis;ng classes of HCV drugs • Phase 2b, 3 month study in combina,on with IFN/RBV an,cipated to c
Slide 10: Key Financials and Facts
Key Financials and Facts BIOTRON ASX Code LIMITED KEY FINANCIALS price BIT history chart Mr Michael Hoy BOARD AND MANAGEMENT Chairman Recent Share Price (23 April 2013) A$0.11 Dr Michelle Miller CEO & Managing Director 52 Week High A$0.185 Dr Denis Wade Non-‐Execu;ve Director 52 Week Low A$0.08 Dr